DADC
OREX

D.A. Davidson & Co’s Orexigen Therapeutics, Inc. OREX Stock Holding History

D.A. Davidson & Co’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-200
Closed -$8K – 2278
2014
Q3 		$8K Hold
200
– – ﹤0.01% 1879
2014
Q2 		$12K Hold
200
– – ﹤0.01% 1781
2014
Q1 		$13K Hold
200
– – ﹤0.01% 1752
2013
Q4 		$11K Buy
+200
New +$11.2K ﹤0.01% 1709

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.A. Davidson & Co's OREX Position: Q4 2014 in Review

D.A. Davidson & Co sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2014, closing a stake of 200 shares — an estimated $8K sold.

D.A. Davidson & Co first reported a position in OREX in Q4 2013 and held it in 4 quarters. The position peaked at $13K in Q1 2014. 147 funds tracked by Wall St. Rank hold OREX as of Q4 2014.

  • D.A. Davidson & Co reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • D.A. Davidson & Co sold 200 Orexigen Therapeutics, Inc. shares in Q4 2014, an estimated $8K.
  • D.A. Davidson & Co first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 4 quarters.
  • D.A. Davidson & Co's Orexigen Therapeutics, Inc. position peaked at $13K in Q1 2014.
  • 147 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2014.

Based on D.A. Davidson & Co's 13F filing for Q4 2014, filed 12 Feb 2015.